Related Experiment Video

Updated: Aug 29, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines

Anna P Durbin1, Ruth A Karron

  • 1Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|December 23, 2003
PubMed

Insights

New live attenuated vaccines for respiratory syncytial virus (RSV) and human parainfluenza viruses (hPIVs) are in clinical trials. Recombinant technology enables fine-tuning of these candidate vaccines to accelerate development against these common respiratory pathogens.

Area of Science:

  • Virology
  • Vaccinology
  • Pediatric Infectious Diseases

Background:

  • Respiratory syncytial virus (RSV) and human parainfluenza viruses (hPIVs) are significant causes of viral lower respiratory tract illness in children and at-risk adults.
  • Despite extensive research, there are currently no licensed vaccines available for RSV and hPIVs.

Purpose of the Study:

  • To highlight the recent advancements in the development of live attenuated vaccines for RSV and hPIVs.
  • To discuss the potential of recombinant technology in accelerating vaccine development against these respiratory viruses.

Main Methods:

  • Generation of genetically engineered live attenuated RSV and hPIV candidate vaccines.
  • Evaluation of these candidate vaccines in ongoing clinical trials.

Main Results:

  • Several genetically engineered live attenuated RSV and hPIV candidate vaccines have been developed.
  • These candidate vaccines are currently undergoing clinical evaluation.

Conclusions:

  • Live attenuated vaccine candidates for RSV and hPIVs show promise for future prevention strategies.
  • Recombinant technology offers a flexible approach to optimize vaccine candidates based on clinical data, potentially speeding up the availability of vaccines for these critical respiratory pathogens.

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Vaccinations01:51

Vaccinations

Overview
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...